Article
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
Breast cancer research and treatment - 2 Apr 2026
Hörner Manuel, Tretschock Lara M, John Nelson, Ziegler Philipp, Häberle Lothar, Uhrig Sabrina, Goossens Chloë, Amann Niklas, Cieslik Jan-Philipp, Dannehl Dominik, Deutsch Thomas M, Dimpfl Moritz, Ehlert Max, Eichstädt Kathleen, Englisch Alexander, Köpke Melitta B, Krückel Annika, Link Theresa, Müller Annika, Reinhardt Kristin, Roth Jonas, Schäffler Henning, Sych Lea, Tegeler Christian M, Wichmann Catharina, Banys-Paluchowski Maggie, Princk Henriette, Rody Achim, Brucker Sara Y, Ditsch Nina, Ettl Johannes, Fehm Tanja, Hack Carolin C, Hadji Peyman, Hein Alexander, Janni Wolfgang W, Kolberg Hans-Christian, Lüftner Diana, Lux Michael P, Müller Volkmar, Schneeweiss Andreas, Taran Florin-Andrei, Tesch Hans, Wallwiener Diethelm, Marmé Frederik, Seitz Stephan, Belleville Erik, Hartkopf Andreas, Michel Laura L, Wallwiener Markus, Fasching Peter A, Tauber Nikolas
Abstract excerpt
PURPOSE: Mutations in PIK3CA are one of several actionable mutations for patients with hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Alpelisib in combination with fulvestrant was the first approved PI3K inhibitor and was introduced in clinical practice in 2019. A lack of evidence for the use of alpelisib in the context of current treatment options like...
Topics
Join the communities discussing this publication.